Tag : cyclophosphamide

Latest News

Rituximab versus cyclophosphamide as first steroid sparing agent in childhood frequently relapsing and steroid dependent nephrotic syndrome

Newsemia
Kari, JA; Alhasan, KA; Albanna, AS; Safder, OY; Shalaby, M; Bockenhauer, D; El-Desoky, SM; (2020) Rituximab versus cyclophosphamide as first steroid sparing agent in childhood...
Latest News

A systematic review and meta-analysis of the gonadotoxic effects of cyclophosphamide and benefits of gonadotropin releasing hormone agonists (GnRHa) in women of child-bearing age with autoimmune rheumatic disease

Newsemia
Luong, S-N; Isaacs, A; Sin, FE; Giles, I; (2020) A systematic review and meta-analysis of the gonadotoxic effects of cyclophosphamide and benefits of gonadotropin releasing...
Latest News

Researchers confirm two new prognostic markers for triple negative breast cancer

Newsemia
Physicians who treat patients with triple negative breast cancer have two new ways to predict which patients may benefit most from the well-established post-surgery treatment...
Latest News

Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis

Newsemia
Smith, E; Al-Abadi, E; Armon, K; Bailey, K; Ciurtin, C; Davidson, J; Gardner-Medwin, J; … Hedrich, CM; + view all Smith, E; Al-Abadi, E; Armon,...
Gastroenterology

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Newsemia
Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint. Source link...
Pharma / Biotech

TYSABRI (Natalizumab) Injection [Biogen Inc.]

Newsemia
Updated Date: Jul 10, 2018 EST...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy